MedStar Authors catalog › Details for: Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice.
Long-term safety and efficacy of the everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. Journal: The Journal of invasive cardiology.ISSN: 1042-3931.UI/PMID: 24717271.Subject(s): Aged | *Coronary Artery Disease/th [Therapy] | Coronary Stenosis/ep [Epidemiology] | Coronary Stenosis/et [Etiology] | Drug-Eluting Stents/ae [Adverse Effects] | *Drug-Eluting Stents | Female | Follow-Up Studies | Humans | Incidence | Longitudinal Studies | Male | Middle Aged | Myocardial Infarction/ep [Epidemiology] | Myocardial Infarction/et [Etiology] | Paclitaxel | *Percutaneous Coronary Intervention/is [Instrumentation] | *Percutaneous Coronary Intervention/mt [Methods] | *Postoperative Complications/ep [Epidemiology] | Postoperative Complications/et [Etiology] | Retrospective Studies | *Sirolimus/aa [Analogs & Derivatives] | Treatment OutcomeInstitution(s): MedStar Heart & Vascular InstituteActivity type: Journal Article.Medline article type(s): Comparative Study | Journal Article | Observational StudyOnline resources: Click here to access online Abbreviated citation: J Invasive Cardiol. 26(4):154-60, 2014 Apr.Local Holdings: Available online from MWHC library: 2001 - present, Available in print through MWHC library: 2003 - 2008.Abstract: OBJECTIVE: This study aimed to assess the long-term safety and clinical effectiveness of the Xience V everolimus-eluting stent (EES) compared to both Taxus paclitaxel-eluting stent (PES) and Cypher sirolimus-eluting stent (SES) in an unselected patient population.Abstract: BACKGROUND: There are limited long-term data comparing Xience V EES vs the first-generation Cypher SES.Abstract: METHODS: This retrospective analysis included 6069 patients treated with Cypher SES, Taxus PES, or Xience V EES from 2003-2009 at our institution. Patients were followed by telephone contact or office visit up to 2 years after the index procedure.Abstract: RESULTS: Baseline characteristics were generally comparable, with the exception of a significantly higher prevalence of diabetes mellitus, systemic hypertension, history of angioplasty, and coronary bypass surgery among Xience V EES patients. At 2 years, the incidence of major adverse cardiovascular events was 13.3% (Xience V EES) vs 17.8% (Cypher SES) vs 22% (Taxus PES) (P<.001). The main drivers for the differences in event rates were lower mortality, the need for target vessel revascularization, and Q-wave myocardial infarction. Stent thrombosis was lowest in Xience V EES patients (0.2% vs 1.2% SES vs 0.7% PES, respectively; P=.01). A landmark analysis after 1 year showed that the benefits of Xience V EES continued in long-term follow-up.Abstract: CONCLUSIONS: In a contemporary clinical United States practice with an unselected patient population, Xience V EES use was associated with improved safety profile and reduction of all-cause mortality and stent thrombosis when compared to both first-generation drug-eluting stents. This superiority continues to widen from 1 to 2 years.